DCN Dx’s Clinical Research Helps Secure FDA Authorization for Cepheid HCV Test

Clinical Research Efforts Supported by NIH-FDA’s ITAP Program and Facilitate De Novo Authorization CARLSBAD, Calif., July 10, 2024 /PRNewswire/ — DCN Dx, a global leader in IVD CDMO and CRO services, is proud to amplify the news that the U.S. Food and Drug Administration (FDA) has…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks